Brainstorm Cell Therapeutics (BCLI) Competitors $0.71 +0.01 (+1.43%) As of 09/26/2025 03:58 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BCLI vs. RENB, TENX, DARE, RNTX, KZR, CVKD, AKTX, MTVA, LIXT, and ENLVShould you be buying Brainstorm Cell Therapeutics stock or one of its competitors? The main competitors of Brainstorm Cell Therapeutics include Lunai Bioworks (RENB), Tenax Therapeutics (TENX), Dare Bioscience (DARE), Rein Therapeutics (RNTX), Kezar Life Sciences (KZR), Cadrenal Therapeutics (CVKD), Akari Therapeutics (AKTX), MetaVia (MTVA), Lixte Biotechnology (LIXT), and Enlivex Therapeutics (ENLV). These companies are all part of the "pharmaceutical products" industry. Brainstorm Cell Therapeutics vs. Its Competitors Lunai Bioworks Tenax Therapeutics Dare Bioscience Rein Therapeutics Kezar Life Sciences Cadrenal Therapeutics Akari Therapeutics MetaVia Lixte Biotechnology Enlivex Therapeutics Lunai Bioworks (NASDAQ:RENB) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends. Which has more risk and volatility, RENB or BCLI? Lunai Bioworks has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.15, meaning that its stock price is 85% less volatile than the S&P 500. Do insiders and institutionals believe in RENB or BCLI? 71.4% of Lunai Bioworks shares are owned by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. 0.5% of Lunai Bioworks shares are owned by insiders. Comparatively, 11.2% of Brainstorm Cell Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts rate RENB or BCLI? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lunai Bioworks 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Brainstorm Cell Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media favor RENB or BCLI? In the previous week, Lunai Bioworks had 8 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 8 mentions for Lunai Bioworks and 0 mentions for Brainstorm Cell Therapeutics. Lunai Bioworks' average media sentiment score of 0.17 beat Brainstorm Cell Therapeutics' score of 0.00 indicating that Lunai Bioworks is being referred to more favorably in the media. Company Overall Sentiment Lunai Bioworks Neutral Brainstorm Cell Therapeutics Neutral Which has preferable valuation & earnings, RENB or BCLI? Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Lunai Bioworks, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLunai BioworksN/AN/A-$88.43M-$0.77-0.17Brainstorm Cell TherapeuticsN/AN/A-$11.62M-$3.10-0.23 Is RENB or BCLI more profitable? Brainstorm Cell Therapeutics' return on equity of 0.00% beat Lunai Bioworks' return on equity.Company Net Margins Return on Equity Return on Assets Lunai BioworksN/A -60.38% -47.04% Brainstorm Cell Therapeutics N/A N/A -519.50% SummaryLunai Bioworks beats Brainstorm Cell Therapeutics on 7 of the 11 factors compared between the two stocks. Get Brainstorm Cell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCLI vs. The Competition Export to ExcelMetricBrainstorm Cell TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.84M$3.12B$5.70B$10.39BDividend YieldN/A2.42%5.78%4.69%P/E Ratio-0.2121.3276.9226.24Price / SalesN/A455.47549.30126.78Price / CashN/A43.2725.6330.64Price / Book-0.529.7312.386.38Net Income-$11.62M-$53.04M$3.31B$274.27M7 Day Performance1.43%1.68%0.22%-0.76%1 Month Performance-6.46%8.57%3.83%6.29%1 Year Performance-78.73%18.28%62.39%27.41% Brainstorm Cell Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCLIBrainstorm Cell Therapeutics0.9571 of 5 stars$0.71+1.4%N/A-78.7%$7.84MN/A-0.2140RENBLunai Bioworks0.7668 of 5 stars$0.16-7.6%N/A-97.4%$30.12MN/A-0.2120Stock SplitGap UpHigh Trading VolumeTENXTenax Therapeutics2.4536 of 5 stars$6.43+0.3%$18.00+179.9%+108.0%$29.25MN/A-6.999Positive NewsDAREDare Bioscience2.2274 of 5 stars$2.04-3.8%$10.00+390.2%-36.1%$28.58M$10K-0.9530RNTXRein Therapeutics2.4661 of 5 stars$1.18-2.5%$10.00+747.5%N/A$28.20MN/A-0.449Positive NewsHigh Trading VolumeKZRKezar Life Sciences3.6739 of 5 stars$3.82+1.6%$9.00+135.6%-32.9%$27.53M$7M-0.3960Positive NewsHigh Trading VolumeCVKDCadrenal Therapeutics2.9885 of 5 stars$13.06-0.8%$32.00+145.0%-3.2%$26.96MN/A-1.474Insider TradeAKTXAkari Therapeutics3.2754 of 5 stars$0.82+0.8%$3.30+302.9%-67.0%$26.50MN/A0.009MTVAMetaVia2.5188 of 5 stars$1.03-1.0%$7.50+628.2%N/A$25.17MN/A0.008LIXTLixte Biotechnology1.1321 of 5 stars$5.42-0.6%N/A+165.3%$24.86MN/A-4.204Gap UpENLVEnlivex Therapeutics2.3663 of 5 stars$1.06+1.0%$10.00+847.6%-37.2%$24.72MN/A-1.8270Analyst Forecast Related Companies and Tools Related Companies RENB Competitors TENX Competitors DARE Competitors RNTX Competitors KZR Competitors CVKD Competitors AKTX Competitors MTVA Competitors LIXT Competitors ENLV Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCLI) was last updated on 9/29/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Brainstorm Cell Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Brainstorm Cell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BCLI Stock Alerts